Two of the nation’s leading lung cancer organizations—the Bonnie J. Addario Lung Cancer Foundation (ALCF) and the Lung Cancer Alliance (LCA)—announced in April their merger to form the GO2 Foundation for Lung Cancer. The new organization, which has offices in Washington, DC, and the San Francisco Bay Area, will capitalize on more than 3 decades of combined expertise, shared philosophy, and complementary programming to maximize resources, expand patient-centered research, and amplify awareness of the challenges and needs facing the lung cancer community.
The GO2 Foundation’s priorities include:
- Serving at-risk patient and caregiver communities through professional, credible, free patient-support services that include personalized screening, treatment, and clinical trial navigation; molecular testing; peer-to-peer mentoring; and support forums
- Advancing world-class academic and community patient-centered research that spans the continuum of care for lung cancer detection, treatment, and survivorship
- Empowering millions to take direct advocacy action for a health-care system that puts the interests of people first to achieve historic increases in federal research funding and new treatment approvals, coverage, and reimbursement for better access and delivery of care
- Expanding access to excellence in screening, care, treatment, and survivorship across all 50 states to ensure that anyone at risk or diagnosed with lung cancer benefits from life-saving services closer to home.
“We are thrilled to blend our talent, resources, commitment, and compassion to create this powerhouse foundation,” said Bonnie J. Addario, lung cancer survivor, Co-Founder, and Chair of the Board of Directors of the GO2 Foundation, and most recently Founder and Chair of ALCF. “The GO2 Foundation will transform what it means to live with lung cancer and increase the patient survival rate…. Together we will continue to break barriers and save lives.”
(L-R) Bonnie J. Addario, lung cancer survivor, Co-Founder, and Chair of the Board of Directors of the GO2 Foundation, and Laurie Fenton Ambrose, Co-Founder, President, and CEO of the GO2 Foundation. Credit: GO2 Foundation for Lung Cancer.
“We are on the cusp of early detection and treatment breakthroughs that will forever alter the future of the disease,” said Laurie Fenton Ambrose, Co-Founder, President, and CEO of the GO2 Foundation, and most recently President and CEO of LCA. “We are seizing this moment to harness this energy and build greater capacity to reach more people with life-saving benefits, personalized care, and comprehensive services that fulfill our credo to ‘Empower Everyone, Ignore No One.’”
The GO2 Foundation is supporting a Conquer Cancer Foundation of ASCO/GO2 Foundation for Lung Cancer 2019 Young Investigator Award.
For more information about the GO2 Foundation, please visit go2foundation.org. ■
© 2019. American Society of Clinical Oncology. All rights reserved.
